Hallucinogen Persisting Perception Disorder (HPPD) Research Initiated By Ehave
Retrieved on:
Thursday, July 29, 2021
MIAMI, July 29, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced plans to launch a series of studies to determine the cause and possible cure for hallucinogen-persisting perception disorder (HPPD). Hallucinogen-persisting perception disorder, or HPPD, can cause a person to keep reliving the visual element of an experience caused by hallucinogenic drugs. Ehave believes the key to widespread acceptance for psychedelics is a focus on the good as well as the bad, which is why we are investing in this series of studies on HPPD.
Key Points:
- HPPD is a psychiatric disorder characterized by the persisting presence of sensory disturbances, most commonly visual, that resemble those produced by the use of hallucinogenic substances.
- Hallucinogen-persisting perception disorder, or HPPD, can cause a person to keep reliving the visual element of an experience caused by hallucinogenic drugs.
- If these visual disturbances occur frequently, you may have a condition called hallucinogen persisting perception disorder (HPPD).
- There have been various individual studies of the condition, but the Ehave study could be the largest patient study to date.